For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …

A growing number of patients undergoing percutaneous coronary intervention (PCI) with
stent implantation also have atrial fibrillation. This poses challenges for their optimal …

Aims Patients at high bleeding risk (HBR) represent a prevalent subgroup among those
undergoing percutaneous coronary intervention (PCI). Early aspirin discontinuation after a …

Aims To validate the set of clinical and biochemical criteria proposed by consensus by the
Academic Research Consortium (ARC) for High Bleeding Risk (HBR) for the identification of …

Importance Patients who are candidates for percutaneous coronary intervention (PCI) and
are at high bleeding risk constitute a therapeutic challenge because they often also face an …

Importance Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …

Aims We aimed to evaluate the validity of the Academic Research Consortium for High
Bleeding Risk (ARC-HBR) criteria for East Asian patients undergoing contemporary …

Aims The five-item PRECISE-DAPT, integrating age, haemoglobin, white-blood-cell count,
creatinine clearance, and prior bleeding, predicts bleeding risk in patients on dual …

Investigating the balance of risk for thrombotic and bleeding events after percutaneous
coronary intervention (PCI) is especially relevant for patients at high bleeding risk (HBR) …

Dual antiplatelet therapy (DAPT) is a therapeutic cornerstone to prevent stent thrombosis
following percutaneous coronary intervention (PCI) for coronary artery disease (CAD) …